SecBot SecBot
3 ·Filed Nov 12, 2026

MTRI

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed4d 11h ago SEC0001193125-26-458264
Actionable Insight • Neutral

These filings confirm the completion of the merger and the resulting insider ownership structure. Monitor future filings for potential insider transactions under the new equity plans and for any registration statements covering the shares issued to Fairmount.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$18.60
T+0 close · Nov 12, 2026 · via day close
Latest settled
+6.83%
T+1 · $19.87
Vs SPY
+8.74%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $18.60entry
  2. T+1 · 20h ago +6.83%α +8.74% · $19.87
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Multiple Form 3 filings were submitted by officers, directors, and a major stockholder of InMed Pharmaceuticals Inc. (now Mentari Therapeutics) following a merger effective November 6, 2026. The filings disclose insider equity holdings and a significant stake by Fairmount Healthcare Fund II L.P., which received over 10.5 million common shares, 4,013 shares of Series A Non-Voting Preferred Stock convertible into 4,013,000 common shares, and pre-funded warrants for 1,468,222 common shares in the merger. The filings are routine post-merger ownership disclosures and do not contain any material financial data or guidance.

Key Facts

  • Effective November 6, 2026, InMed Pharmaceuticals Inc. completed a merger with Mentari Therapeutics Inc., with the issuer renamed Mentari Therapeutics Inc.
  • Brett Hagen (SVP, Finance and CAO) received options to purchase 62,273 shares at $10.37 per share, vesting over 4 years.
  • Jerad G. Seurer (General Counsel and Corporate Secretary) received options to purchase 93,411 shares at $10.37 per share, vesting over 4 years.
  • Fairmount Healthcare Fund II L.P. received 10,555,507 common shares, 4,013 shares of Series A Non-Voting Preferred Stock (convertible into 4,013,000 common shares), and pre-funded warrants for 1,468,222 common shares in the merger.
  • The exchange ratio for Pre-Merger Mentari common stock and Series A Preferred Stock was 0.20065 shares of issuer common stock per share.
  • Todd Shegog filed a Form 3 but reported no securities owned.
  • All filings include Powers of Attorney authorizing officers to execute future Section 16 filings.

Financial Impact

No financial figures disclosed beyond option exercise prices and share counts.

Risk Factors

  • Potential dilution from the conversion of Series A Preferred Stock (up to 4,013,000 common shares) and exercise of pre-funded warrants (1,468,222 common shares).
  • Beneficial ownership limitation of 19.99% on Fairmount's holdings may affect future conversion/exercise timing.

Investment Themes

Documents Analyzed

This report is based on 15 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (MTRI), Batch item 10001193125-26-458264
Document: 0001193125-26-458264-index-headers.html0001193125-26-458263
Document: 0001193125-26-458264-index.html0001193125-26-458262
Document: 0001193125-26-458264.txt0001193125-26-458261
3 Filing (MTRI), Batch item 50001193125-26-458263
Document: 0001193125-26-458263-index-headers.html0001193125-26-458264
Document: 0001193125-26-458263-index.html0001193125-26-458264
Document: 0001193125-26-458263.txt0001193125-26-458264
3 Filing (MTRI), Batch item 90001193125-26-458262
Document: 0001193125-26-458262-index.html0001193125-26-458264
Document: 0001193125-26-458262.txt0001193125-26-458264
3 Filing (MTRI), Batch item 120001193125-26-458261
Document: 0001193125-26-458261-index-headers.html0001193125-26-458264
Document: 0001193125-26-458261-index.html0001193125-26-458264
Document: 0001193125-26-458261.txt0001193125-26-458264

US Market Status

Market Closed · Opens in 6h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026